Physician profile
Alan E Rolfe
NPI 1295899953
$2,440.15
in general payments reported to CMS, 2019-2025
23 companies · $57.59 in 2025
The $57.59 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $307 · 2021: $415 · 2022: $225 · 2023: $617 · 2024: $350 · 2025: $57.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $340.65 | 2021-2025 | |
| Ucb, INC. | $296.36 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $273.78 | 2021-2024 | |
| Janssen Biotech, INC. | $235.15 | 2020-2024 | Tremfya |
| Incyte Corporation | $174.59 | 2023-2024 | Opzelura |
| Dermira, INC. | $148.59 | 2019 | |
| Sun Pharmaceutical Industries INC. | $142.48 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $114.21 | 2021-2023 | Libtayo |
| Abbvie INC. | $99.92 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.93 | 2023 | Siliq |
| Celgene Corporation | $80.68 | 2019 | |
| Genzyme Corporation | $70.52 | 2020-2021 | |
| Leo Pharma INC. | $64.49 | 2019-2024 | Adbry |
| Stemline Therapeutics INC. | $57.11 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.37 | 2024 | Sotyktu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.48 | 2022 | |
| Lilly USA, LLC | $24.97 | 2023 | Taltz, Olumiant |
| Amgen INC. | $23.14 | 2019 | |
| Vyne Pharmaceuticals INC. | $22.85 | 2020 | |
| Galderma Laboratories, L.P. | $17.03 | 2020 | |
| Genentech USA, INC. | $16.95 | 2020 | |
| Merck Sharp & Dohme LLC | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Rolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.